Company: RGNT
Filing Date: 2025-09-30
Form Type: F-1/A
Source: 0001213900-25-093302
Chunk: 18

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-09-30
Form: F-1/A
Chunk 18
---
 collaborators or distributors in the United States, Europe and other potential markets    
 that we will target;                                                                                                                   |

| ● | accurately identifying                                                    
 demand for our Gelrin hydrogel platform or any future product candidates; |

<div align='center'>16</div>

| ● | expose and educate physicians                               
 and other medical professionals to the use of our products; |

| ● | obtain market acceptance                                                                                             
 of our Gelrin hydrogel platform and any future product candidates from the medical community and third-party payors; |

| ● | ensure our product candidates                                                                                                       
 are approved for reimbursement from governmental agencies, health care providers and insurers in jurisdictions where they have been 
 approved for marketing;                                                                                                             |

| ● | address any competing technological                                                                                              
 and market developments that impact our Gelrin hydrogel platform and any future product candidates or their prospective usage by 
 medical professionals;                                                                                                           |

| ● | negotiate favorable terms                                                                                                            
 in any collaboration, licensing or other arrangements into which we may enter and perform our obligations under such collaborations; |

| ● | maintain, protect and expand                                                                                       
 our portfolio of intellectual property rights, including patents, patent applications, trade secrets and know-how; |

| ● | avoid and defend against                             
 third-party interference or infringement claims; and |

| ● | attract, hire and retain 
 qualified personnel.     |

We
anticipate incurring significant incremental costs associated with commercializing such product candidates. Our expenses could increase
beyond expectations if we are required by the FDA, or other regulatory agencies, domestic or foreign, to change our manufacturing processes
or assays or to perform studies in addition to those that we currently anticipate. Even if we are successful in obtaining additional
regulatory approvals to market our GelrinC or any future product candidates, our revenue earned from such product candidates will be
dependent in part upon the size of the markets in the territories for which we gain regulatory approval for such products, the accepted
price for such products, our ability to obtain reimbursement for such products at any price, whether we own the commercial rights for
that territory in which such products have been approved and the expenses associated with manufacturing and marketing such products for
such markets. Therefore, we may not generate significant revenue from the sale of such products. Further, if we are not able to generate
significant revenue from the sale of our approved products, we may be forced to curtail or cease our operations. Due to the numerous
risks and uncertainties involved in product development, it is difficult to predict the timing or amount of